Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by macman1519on Jan 14, 2018 11:36pm
83 Views
Post# 27356148

RE:RE:Patient #4 HAS ACHIEVED primary and secondary endpoint

RE:RE:Patient #4 HAS ACHIEVED primary and secondary endpointLol scraping the barrel to blast our results and this is it, this is all u come up with??? UR Fukked and u know it!!!  Wow 2412 patients, 15 centres, 37 months !!! Impressive???? What were the results scumbag ? How many went 90 days cancer free, scumbag??? Did 100% have no cancer progression for 180 days, moron??  You dont tell us those results cuz they dont compare with ours,  slimebag!!  U R THE WORST DEBATER I HAVE EVER MET, you have no clue how to use facts!! Guess its cus u have none to use, so its obfuscate, lie and exaggerate are ur only means of negativity! Ur a fool and everybody knows it, Yaz, u and the fukkin choir, scumbags!!!! 


uote=bionicjoe]What're 90 days? A Korean study on NMIBC recurrence and progression tested 2412 patients from 15 centers for 37 months. The deeper you go into the timeline the more you can draw valid conclusions. All shareholders ever get is excuses why things didn't happen. How about for once they are treated to no excuses, just terrific news.


[/quote]

Bullboard Posts